May 4 (Reuters) - Regeneron Pharmaceuticals Inc's (REGN.O), opens new tab first-quarter sales of blockbuster eye drug Eylea came in below Wall Street targets on Thursday as competition heated up ...

April 29 (Reuters) - Regeneron's (REGN.O), opens new tab first-quarter results missed Wall Street estimates on Tuesday due to stiff competition for its blockbuster drug Eylea, further stoking ...

Eylea is a widely used biologic for the treatment of eye disorders, including diseases which can lead to vision loss or blindness, such as wet AMD, macular edema, and diabetic retinopathy.

Regeneron (NASDAQ:REGN) said on Thursday that the U.S. FDA will be reviewing a supplemental biologics license application ((sBLA)) for its eye disease drug Eylea HD injection, 8 mg, to expand its ...